CoChat
Cited by 225

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma

Open access
Barsoumian, Hampartsoum B, Ramapriyan, Rishab, Younes, Ahmed I, Caetano, Mauricio S, Menon, Hari, Comeaux, Nathan I, Cushman, Taylor R, Schoenhals, Jonathan E, Cadena, Alexandra P, Reilly, Timothy P, Chen, Dawei, Masrorpour, Fatemeh, Li, Ailin, Hong, David S, Diab, Adi, Nguyen, Quynh-Nhu, Glitza, Isabella, Ferrarotto, Renata, Chun, Stephen G, Cortez, Maria Angelica, Welsh, James · 2020 · Journal for ImmunoTherapy of Cancer

Abstract

Background: Despite some successes with checkpoint inhibitors for treating cancer, most patients remain refractory to treatment, possibly due to the inhibitory nature of the tumor stroma that impedes the function and entry of effector cells. We devised a new technique of combining immunotherapy with radiotherapy (XRT), more specifically low-dose XRT, to overcome the stroma and maximize systemic outcomes. Methods: We bilaterally established 344SQ lung adenocarcinoma tumors in 129Sv/Ev mice. Primary and secondary tumors were irradiated with either high-dose or low-dose of XRT with systemic anti-programmed cell death protein 1 and anti-cytotoxic T-lymphocyte associated protein 4 administration. Survival and tumor growth were monitored for the various groups, and secondary tumors were phenotyped by flow cytometry for immune populations. Tumor growth factor-beta (TGF-β) cytokine levels were assessed locally after low-dose XRT, and specific immune-cell depletion experiments were conducted to identify the major contributors to the observed systemic antitumor effect. Results: Through our preclinical and clinical studies, we observed that when tumor burden was high, there was a necessity of combining high-dose XRT to ‘prime’ T cells at the primary tumor site, with low-dose XRT directed to secondary (metastatic) tumors to ‘modulate the stroma’. Low-dose XRT improved the antitumor outcomes of checkpoint inhibitors by favoring M1 macrophage polarization, enhancing natural killer (NK) cell infiltration, and reducing TGF-β levels. Depletion of CD4+ T cells and NK cells abrogated the observed antitumor effect. Conclusion: Our data extend the benefits of low-dose XRT to reprogram the tumor environment and improve the infiltration and function of effector immune cells into secondary tumors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/jitc-2020-000537

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 225

Metadata

Authors
Barsoumian, H. B., Ramapriyan, R., Younes, A. I., Caetano, M. S., Menon, H., Comeaux, N. I., Cushman, T. R., Schoenhals, J. E., Cadena, A. P., Reilly, T. P., Chen, D., Masrorpour, F., Li, A., Hong, D. S., Diab, A., Nguyen, Q.-N., Glitza, I., Ferrarotto, R., Chun, S. G., Cortez, M. A., & Welsh, J.
Venue
Journal for ImmunoTherapy of Cancer
Publisher
BMJ
Published
2020-10
Volume
8
Issue
2
Pages
e000537
ISSN
2051-1426 (ISSN-L)
OpenAlex
W3094422108
Cited by
225
References
5
FWCI
8.18
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma. https://app.cochat.ai/papers/10.1136/jitc-2020-000537
The paper
Barsoumian, H. B., Ramapriyan, R., Younes, A. I., Caetano, M. S., Menon, H., Comeaux, N. I., Cushman, T. R., Schoenhals, J. E., Cadena, A. P., Reilly, T. P., Chen, D., Masrorpour, F., Li, A., Hong, D. S., Diab, A., Nguyen, Q.-N., Glitza, I., Ferrarotto, R., Chun, S. G., . . . Welsh, J. (2020). Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2020-000537

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.